Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01818245 · ClinicalTrials.gov registry record · Phase 1
A Study of LY2605541 in Healthy Participants and in the Elderly
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT01818245 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 52 participants.
The verdict
NCT01818245, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
This study will include 2 groups (cohorts) of participants: In Cohort A, this study will look at the amount of LY2605541 that is present in the body after it is injected in 3 different locations in the body of the same participant. At least 16 days will pass between each injection. In Cohort B, the study will look at how the body absorbs, distributes, and disposes of LY2605541 in participants aged 65 and over. Participants may enroll in only one cohort.
Interventions
- DRUG LY2605541
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2013-03 |
| Est. Completion | 2013-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01818245
The ClinicalTrials.gov registry entry for NCT01818245 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which LY2605541 is the first listed.
NCT01818245 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01818245 about?
NCT01818245 is a clinical study titled "A Study of LY2605541 in Healthy Participants and in the Elderly". This study will include 2 groups (cohorts) of participants: In Cohort A, this study will look at the amount of LY2605541 that is present in the body after it is injected in 3 different locations in the body of the same participant. At least 16 days will pass between each injection. In Cohort B, th...
What is the current status of trial NCT01818245?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2013-03. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01818245?
The interventions under investigation include: LY2605541 (DRUG).
Who is sponsoring clinical trial NCT01818245?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.